ADTX Executes Major 1-for-250 Reverse Stock Split to Meet Nasdaq Listing Requirements

Aditxt, Inc. (NASDAQ: ADTX) is moving forward with a significant restructuring of its capital structure. The company unveiled its plans to implement a 1-for-250 reverse stock split, effective when markets open on March 17, 2025. This corporate action, approved by shareholders during a special meeting on February 28, 2025, will see the company’s common stock continue trading under its existing ticker symbol ADTX on the Nasdaq Capital Market.

What Changes for Shareholders

Under the new arrangement, every 250 shares of currently held common stock will convert into a single share, with fractional shares being rounded up to the nearest whole number. Following the effective date, Aditxt will have approximately 1,031,110 shares outstanding. The company’s CUSIP identifier will shift to 007025802 to reflect this restructuring.

Why the Move Matters

The reverse split primarily addresses Aditxt’s compliance status with Nasdaq’s minimum bid price standards. By consolidating shares, the company aims to elevate per-share valuation metrics, a common strategy for companies working to maintain listing standards on major exchanges.

Aditxt’s Strategic Direction

Aditxt positions itself as a collaborative innovation platform targeting healthcare breakthroughs. The company operates through distinct programs focused on immune health and precision health, with expansion plans underway for public health and women’s health initiatives.

The company is progressing through strategic arrangements with Appili Therapeutics, Inc. (TSX: APLI; OTCPink: APLIF), a player in infectious disease research, and discussions regarding a potential merger with Evofem Biosciences, Inc. (OTCQB: EVFM). These initiatives would expand Aditxt’s program portfolio. However, the transactions remain contingent on various conditions, including shareholder approval and Aditxt successfully raising capital. The company estimates needing approximately $17 million each for both Appili and Evofem transactions.

Notably, Evofem withdrew its merger proposal from stockholder consideration in late December 2024, introducing uncertainty around that particular transaction’s completion.

Further details regarding the reverse stock split are available in Aditxt’s proxy statement filed with the Securities and Exchange Commission on January 27, 2025.